For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

ARA-290

Also known as: Cibinetide

ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.

Where to buy · live market data

Who's worth your money for ARA-290

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 20 scored sellers

$5.50/mg

$54.99 · 10mg · 100.0% purity

2 COAs
Buy code MERIT · 10% off

Best value after code

$2.39/mg effective with 10% code

$2.66/mg

$42.50 · 16mg · 99.5% purity

1 COA
Buy code CRAFTERS10 · 10% off

Most tested

6 independent COAs on file

$3.25/mg

$39.00 · 12mg · 98.4% purity

Average price

$5.26/mg

Sellers

47

45-day trend

-9.1%

39 of 47 sellers have a current price· 12 stale hidden· 7 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch ARA-290

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About ARA-290

CAS

1208243-50-8

Molecular formula

C51H84N16O21

Sequence

UEQLERALNSS

Typical dose range

4 mg/day subcutaneous (clinical trial dosing for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy)

Half-life

~20 minutes terminal half-life (after 4 mg SC injection; biological effect may persist 24–72 hours)

Independent evidence

COAs for ARA-290

56 third-party tests across 20 vendors. Each card links to the full report.

All 56 COAs for ARA-290 →
Measured purity 98.2%–100.0% across 43 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.97 %
Aug 2026
Janoshik Analytical Limited

For

ARA-290

by Longeva· batch B-2026-ARA-290-10-002

Aggregated · 3rd-party listing
99.00 %
Jul 2026
Ethos Analytics Strong

For

ARA-290

by OROS Research· batch OR-LPARA32-726-B2

Aggregated · 3rd-party listing
99.73 %
Jul 2026
ILS Labs Strong

For

ARA-290

by Ion Peptide· batch RA10-06172026

✓ Vendor-published
99.80 %
Jul 2026
ILS Laboratories

For

ARA-290

by Ion Peptide· batch RA10-06172026

COA on file
✓ Vendor-published
99.92 %
Jun 2026
Freedom Diagnostics Moderate

For

ARA-290

by Ion Peptide· batch RA16-06242026

COA on file
Aggregated · 3rd-party listing
99.92 %
Jun 2026
Freedom Diagnostics Moderate

For

ARA-290

by Ion Peptide· batch RA16-06242026

Aggregated · 3rd-party listing
99.32 %
Jun 2026
Kovera Labs

For

ARA-290

by Real Peptides· batch BATCH-0322

Aggregated · 3rd-party listing
99.83 %
Jun 2026
Janoshik Analytical Limited

For

ARA-290

by EZ Peptides· batch EZP-ARA1005192026-03

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

ARA-290

by OROS Research· batch OR-LPARA32-526-B1

✓ Vendor-published
99.83 %
Jun 2026
Janoshik Analytical Limited

For

ARA-290

by EZ Peptides· batch EZP-ARA1005192026-03

COA on file
Aggregated · 3rd-party listing
99.43 %
May 2026
ILS Labs Strong

For

Ara-290

by Ion Peptide· batch ARA16-05202026

✓ Vendor-published
99.43 %
May 2026
ILS Laboratories

For

Ara-290

by Ion Peptide· batch ARA16-05202026

COA on file
Aggregated · 3rd-party listing
99.23 %
Apr 2026
ILS Labs Strong

For

ARA-290

by Riptide Wellness· batch RWARA-10-1002

Aggregated · 3rd-party listing
98.37 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

ARA-290

by Verified Peptides· batch ARA04260312C

✓ Vendor-published
98.37 %
Apr 2026
Janoshik Analytical Limited

For

ARA-290

by Verified Peptides· batch ARA0426031 2C

COA on file
Aggregated · 3rd-party listing
99.97 %
Mar 2026
Kovera Labs

For

ARA-290

by Glacier Aminos· batch ARA10GA-01

Aggregated · 3rd-party listing
99.47 %
Mar 2026
Janoshik Analytical Limited

For

ARA-290

by Peptide Crafters· batch PC-G1-AR16

Aggregated · 3rd-party listing
99.41 %
Feb 2026
Freedom Diagnostics Moderate · HPLC

For

ARA-290

by Peptide Supply Co.· batch AR1022026

Aggregated · 3rd-party listing
99.12 %
Feb 2026
Freedom Diagnostics Moderate

For

ARA-290

by Modern Research Peptides· batch LCHK262

Aggregated · 3rd-party listing
99.74 %
Jan 2026
BioRegen Moderate · HPLC

For

ARA-290

by BioLongevity Labs· batch 2-3-46035

✓ Vendor-published
99.90 %
Jan 2026
Freedom Diagnostics Moderate

For

ARA-290

by Ion Peptide· batch ARA10-01212026

COA on file
Aggregated · 3rd-party listing
99.90 %
Jan 2026
Freedom Diagnostics Moderate

For

ARA-290

by Ion Peptide· batch ARA10-01212026

Aggregated · 3rd-party listing
99.77 %
Jan 2026
MDx BioAnalytical Laboratory Strong · HPLC

For

ARA-290

by BioLongevity Labs· batch cmojb6w60016nkirxxcy5khmm

Aggregated · 3rd-party listing
99.56 %
Jan 2026
Freedom Diagnostics Moderate

For

ARA-290

by Southern Aminos· batch AR100126A

Research depth

16 citations indexed for ARA-290

All research on ARA-290 →

animal · 2026

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice

Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.

review · 2026

Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management

Purpose of review This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-relate…

review · 2025

Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging

Cardiology is continually evolving towards increased personalization with targeted diagnostics and therapeutics.

animal · 2022

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression

Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets.

animal · 2021

Synthesis and evaluation of <sup>99m</sup>Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region

Objectives Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs.

animal · 2016

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets

Background Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties.